{"id":"NCT01095653","sponsor":"AstraZeneca","briefTitle":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2012-03","completion":"2012-03","firstPosted":"2010-03-30","resultsPosted":"2017-02-06","lastUpdate":"2017-02-06"},"enrollment":1179,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Metformin","otherNames":["GlucophageÂ®"]},{"type":"DRUG","name":"Dapagliflozin Placebo","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can improve (decrease) blood glucose values in Asian patients with Type 2 Diabetes who have never been treated with medication or have been on medication for less than 24 weeks since their original diagnosis of Diabetes. The safety of this treatment will also be studied.","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.29,"sd":0.0681},{"arm":"Dapagliflozin 5 mg","deltaMin":-1.04,"sd":0.0695},{"arm":"Dapagliflozin 10 mg","deltaMin":-1.11,"sd":0.068}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":39,"countries":["China","India","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":["https://www.ncbi.nlm.nih.gov/pubmed?term=%22Clinical+therapeutics%22%5BJour%5D+AND+2014%5Bpdat%5D+AND+Dapagliflozin&TransSchema=title&cmd=detailssearch&_sm_au_=iFHnRDqNTf1p01TQ"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":132},"commonTop":["HYPERLIPIDAEMIA","UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","DYSLIPIDAEMIA"]}}